Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of famitinib combined with camrelizumab in advanced thyroid cancer
ChiCTR1900026894Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of famitinib and camrelizumab in thyroid cancer, well-differentiated thyroid cancer (WDTC), Medullary Thyroid Cancer (MTC) and 1 more (3 cohorts), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Oct 2019; status: recruiting.
02
Drugs
famitinibcamrelizumab
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)Medullary Thyroid Cancer (MTC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on ChiCTR1900026894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026894.